Aquestive Therapeutics (AQST) Debt to Equity: 2017-2025
Historic Debt to Equity for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to -$8.83.
- Aquestive Therapeutics' Debt to Equity fell 1181.69% to -$8.83 in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.10, marking a year-over-year decrease of 4996.83%. This contributed to the annual value of -$0.54 for FY2024, which is 109.14% down from last year.
- Aquestive Therapeutics' Debt to Equity amounted to -$8.83 in Q3 2025, which was down 1,729.52% from -$0.48 recorded in Q2 2025.
- Aquestive Therapeutics' Debt to Equity's 5-year high stood at -$0.26 during Q4 2023, with a 5-year trough of -$8.83 in Q3 2025.
- Its 3-year average for Debt to Equity is -$1.28, with a median of -$0.54 in 2024.
- In the last 5 years, Aquestive Therapeutics' Debt to Equity soared by 74.88% in 2021 and then plummeted by 1,181.69% in 2025.
- Aquestive Therapeutics' Debt to Equity (Quarterly) stood at -$0.65 in 2021, then surged by 32.57% to -$0.44 in 2022, then skyrocketed by 41.23% to -$0.26 in 2023, then tumbled by 109.14% to -$0.54 in 2024, then plummeted by 1,181.69% to -$8.83 in 2025.
- Its Debt to Equity stands at -$8.83 for Q3 2025, versus -$0.48 for Q2 2025 and -$0.55 for Q1 2025.